Gala Health Tirzepatide Review: Cost, Compounded vs Brand & Honest Verdict (2026)

Gala Health is a low-cost compounded telehealth program with a rare combination for its price point: $179/month compounded tirzepatide (with a cheaper $149 microdose tier), availability in all 50 states, and a brand-name pathway if you specifically want the FDA-approved product. This review covers what Gala is, what it dispenses, the compounded-versus-brand distinction, its real pricing, and the catches. We disclose an affiliate relationship with Gala; it never changes our scoring, and every fact here comes from Gala's own program.

What Gala Health is

Gala Health (operated by AI Coaching Inc) is a telehealth weight program. A licensed prescriber reviews an online intake and, where appropriate, compounded tirzepatide ships for $179/month, with a lower $149/month microdose tier and 3-month bundles starting at $199. Unusually for a compounded provider at this price, Gala is available in all 50 states. It also offers a brand-name pathway (Ozempic) for patients who specifically want the FDA-approved product, plus HRT and menopause care under the same roof.

The compounded-vs-brand question

Two very different products share the name tirzepatide:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact molecule and dose studied in the pivotal trials.
• •Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

Gala's headline $179/month tirzepatide is compounded, which is why it sits far below brand pricing. That matters more in 2026: the FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement discretion that permitted routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies, March 19, 2025 for 503B outsourcing facilities) — the full timeline is in our guide to whether compounded tirzepatide is still legal in 2026. Note that Gala's brand-name pathway is for Ozempic (semaglutide), a different molecule from tirzepatide, and it is priced very high (see below), so it is not a cheap route to the brand tirzepatide drug.

What Gala Health costs in 2026

Gala publishes low compounded prices: $179/month for compounded tirzepatide, an even cheaper $149/month microdose tier, and 3-month plans from $199. The standout is that this low pricing comes with all-50-state coverage, which most compounded-only startups cannot match. The brand-name option — Ozempic at $1,299 — is very expensive and is a different molecule, so it is best understood as an add-on for patients who specifically want brand semaglutide rather than a competitive tirzepatide route.

For context on the brand tirzepatide drug, LillyDirect sells brand Zepbound self-pay vials at roughly $299–$449/month depending on dose (prices effective February 23, 2026; 28-day supply). Gala's compounded tirzepatide undercuts that, but you are comparing a non-FDA-approved product to the approved one. For the full cash-price picture, see our Zepbound cost and savings guide.

How the care model holds up

Gala's strengths are a genuinely low compounded entry price ($179/month, or $149 microdose), all-50-state availability that is rare at this price, a brand pathway for patients who want it, and adjacent HRT/menopause care. The trade-offs: the tirzepatide is compounded and not FDA-approved; the brand Ozempic option is very expensive at $1,299 and is a different molecule; there is no oral tirzepatide pathway yet; and Gala is a newer operator with a shorter track record than established platforms. As with any GLP-1 service, confirm continuity of care and read the cancellation terms; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Separate the provider from the medication, and the brand molecule from a compounded copy. Brand tirzepatide's efficacy is trial-grade: in the 72-week SURMOUNT-1 trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo¹; against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14%². Those results were established with the brand molecule; compounded versions were never tested in those trials. Note too that a microdose tier uses lower-than-standard doses, so it should not be expected to match full-dose trial results. The full picture is in our tirzepatide evidence guide and our look at tirzepatide microdosing.

The honest verdict

Gala Health is a strong value pick if you want low-cost compounded tirzepatide with rare all-50-state coverage and are comfortable with a compounded, non-FDA-approved product from a newer operator. The reservations are the shorter track record, the lack of an oral pathway, and the fact that its brand option (Ozempic, $1,299) is a pricey, different-molecule add-on rather than a cheap brand-tirzepatide route. If you want a flat price with included nurse/dietitian support, weigh CoreAge Rx; if you specifically want brand tirzepatide, price it against LillyDirect. See our best tirzepatide providers ranking and best place to get Zepbound online roundup.